Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)

The summary for the Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42): The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.

Federal Grant Title:	Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-17-036
Type of Funding:	Grant
CFDA Numbers:	93.350, 93.855, 93.856
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 5th, 2019
Original Application Deadline:	September 5th, 2019
Posted Date:	October 27th, 2016
Creation Date:	October 27th, 2016
Archive Date:	October 6th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 27th, 2016

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-17-036.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) f...; • Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed); • Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...; • Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not...; • Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science ...; • Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...; • A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...; • Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)